Genmab A/S (NASDAQ:GMAB) Shares Sold by Wells Fargo & Company MN

Wells Fargo & Company MN lessened its holdings in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 59.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 283,111 shares of the company's stock after selling 417,293 shares during the period. Wells Fargo & Company MN's holdings in Genmab A/S were worth $5,909,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of GMAB. Brandywine Global Investment Management LLC purchased a new position in shares of Genmab A/S during the 4th quarter worth $33,804,000. JPMorgan Chase & Co. boosted its stake in Genmab A/S by 3,049.3% during the fourth quarter. JPMorgan Chase & Co. now owns 407,613 shares of the company's stock worth $8,507,000 after buying an additional 394,670 shares during the period. Trexquant Investment LP increased its position in shares of Genmab A/S by 495.1% during the fourth quarter. Trexquant Investment LP now owns 379,936 shares of the company's stock valued at $7,929,000 after acquiring an additional 316,089 shares during the last quarter. ABC Arbitrage SA purchased a new stake in shares of Genmab A/S in the 4th quarter valued at approximately $3,692,000. Finally, AIMZ Investment Advisors LLC acquired a new position in shares of Genmab A/S in the 4th quarter worth approximately $3,525,000. Institutional investors and hedge funds own 7.07% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on GMAB shares. William Blair upgraded Genmab A/S from a "market perform" rating to an "outperform" rating in a research report on Tuesday, March 11th. Sanford C. Bernstein lowered shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a research note on Tuesday, April 1st. HC Wainwright restated a "buy" rating and issued a $37.00 price objective (down previously from $50.00) on shares of Genmab A/S in a report on Wednesday, April 9th. BNP Paribas upgraded shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a report on Tuesday, February 11th. Finally, Leerink Partnrs upgraded shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a research note on Thursday, February 13th. One analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $39.17.

Genmab A/S Stock Performance

NASDAQ GMAB traded down $0.18 during trading on Wednesday, reaching $20.09. 997,031 shares of the company's stock were exchanged, compared to its average volume of 1,043,800. The company has a 50 day moving average price of $20.53 and a two-hundred day moving average price of $21.11. The stock has a market cap of $13.29 billion, a P/E ratio of 11.55, a price-to-earnings-growth ratio of 2.65 and a beta of 1.07. Genmab A/S has a 1 year low of $17.24 and a 1 year high of $30.41.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. Research analysts forecast that Genmab A/S will post 1.45 EPS for the current fiscal year.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.